Members do not see these Ads.
Sign Up .
Forbes are reporting:
The Diabetes-Industrial Complex
While it would be easy to pontificate on how this growing patient population can be seen as both good and bad, there is actually a bigger problem on the horizon, a problem that's hidden but becoming larger each day.
A few years ago Diabetic Investor speculated that in an effort to expand the market for diabetes medications, the industry would actively promote this new condition called pre-diabetes. The industry just wasn't content to have a diabetes epidemic; they figured their share prices would increase when investors realized that the market wasn't limited to the 24 million with actual diabetes. The market was actually closer to 100 million patients when you include the 57 million consumers with "pre-diabetes."
Click to expand...
Today, you can't swing a dead cat without hearing the term "pre-diabetes"--and not just from companies in the drug business. Researchers and physicians have embraced this new condition as well. Physicians are now diagnosing patients with "pre-diabetes" and prescribing medications to prevent the patient from developing full-blown diabetes. As well intentioned as these efforts are, this fascination with "pre-diabetes" has created an even bigger problem. Diabetic Investor calls this problem the "I don't have what you have" syndrome.
Click to expand...
From a business perspective, one has to wonder how companies like Novo Nordisk, Amylin Pharmaceuticals, Eli Lilly and Johnson & Johnson will respond to this infatuation with "pre-diabetes."
On one hand, it has the potential to help sales as more consumers become aware of diabetes. On the other, it could backfire.
Will the industry speak out against "pre-diabetes" and push for a clear definition of who has and who does not have diabetes? Or will it continue to remain silent in the hopes that the 57 million consumers with "pre-diabetes" will develop full-blown diabetes, increasing the market for drugs and devices.
Click to expand...
Full story